(Circulation. 2000;101:224.)
© 2000 American Heart Association, Inc.
Brief Rapid Communications |
From the Heart Research Institute (J.A.M., S.N., W.J., K.K.S., D.S.C.) and Department of Cardiology (J.A.M., D.S.C.), Royal Prince Alfred Hospital in Missenden Road, and the Department of Medicine, University of Sydney (A.K.D., D.J.H., D.S.C.), Sydney, Australia.
Correspondence to Dr David S. Celermajer, Department of Cardiology, Royal Prince Alfred Hospital, Missenden Road, Camperdown, Sydney, 2050, Australia. E-mail davidc{at}card.rpa.cs.nsw.gov.au
| Abstract |
|---|
|
|
|---|
Methods and ResultsPrimary human monocytes were allowed to differentiate into macrophages. RNA was then extracted from healthy male-donor (n=8) and premenopausal female-donor (n=8) macrophages, and message for the androgen receptor (AR) was examined by RT-PCR. There was a significantly higher level of AR mRNA in macrophages isolated from men than in those from women (0.64±0.06 versus 0.15±0.02 amol/µg total RNA; P<0.001). AR mRNA levels were similar in macrophages from postmenopausal and premenopausal women (P=0.16). The functional consequence of this sex difference was then explored. Lipid-loading studies were performed on male (n=9) macrophages treated with the androgen dihydrotestosterone (DHT) and/or the AR antagonist hydroxyflutamide. These showed that DHT caused a dose-dependent and receptor-mediated increase in macrophage cholesteryl ester content (109±10%, 117±3%, and 120±4% for 4, 40, and 400 nmol/L DHT, respectively, as a percentage of control, P=0.002; 95±8% for DHT with hydroxyflutamide, P=0.58 versus controls). By contrast, there was no significant effect of androgen on lipid loading in female-donor macrophages (P>0.2 versus controls).
ConclusionsSex differences in androgen-mediated macrophage lipid loading may contribute to the greater prevalence and severity of atherosclerosis in men.
Key Words: atherosclerosis cells hormones
| Introduction |
|---|
|
|
|---|
Foam cell formation is a key early event in atherosclerosis and is largely due to the uptake of modified lipoproteins, principally LDL, by peripheral blood monocyte-derived macrophages (MDMs) in the arterial wall.6 7 The possibility that androgen receptors (ARs) and androgen-related intracellular pathways may be involved in the process of lipid loading and foam cell formation in atherosclerosis has not been explored previously. We therefore investigated whether the AR is expressed in primary human MDMs and whether there is a sex difference in its expression and have examined the biological effects of androgen stimulation on cholesteryl ester (CE) formation/lipid loading in these cells.
| Methods |
|---|
|
|
|---|
Culture and Analysis of Human MDMs
Monocytes isolated by elutriation were resuspended in phenol
redfree RPMI (Life Technology) and allowed to adhere for
1.5 hours
at 37°C under 5% CO2 in air. Thereafter,
phenol redfree RPMI containing 10% postmenopausal female human serum
(17ß-estradiol <75 pmol/L, progesterone <0.8 nmol/L, and
testosterone <2 nmol/L), penicillin G (50 U/mL), and streptomycin (50
µg/mL) was added. Changes of medium occurred every 2 to 3 days, and
hormone treatments (dihydrotestosterone, DHT, Sigma, at 4 to 400 nmol/L
with or without the AR antagonist hydroxyflutamide, HF, 400
nmol/L) were added from days 3 through 10 with each change of medium.
In the control conditions, no DHT or HF was added. Serum testosterone
levels in healthy men range from
4 to 40 nmol/L. Lipid loading was
achieved on days 8 through 10 during a 48-hour incubation with 50
µg/mL of acetylated LDL in medium containing 10% (vol/vol)
lipoprotein-deficient human serum (d>1.25). Cell viability
for each treatment condition was 90% to 95%. LDL was isolated from
plasma from healthy, normolipidemic subjects, and macrophage
cell extracts were analyzed by high-performance liquid
chromatography according to previously described
methods.9
RNA Extraction and Measurement of AR mRNA Levels
After 7 to 8 days of culture in RPMI supplemented with
postmenopausal serum, male- and female-donor MDMs were assessed for AR
message.
Total RNA was extracted from each male- and female-donor experiment (1.5x106 macrophages per well), and RNA was quantified with the SYBR Green II assay (Molecular Probes).10 Androgen and ß-actin (control) primers were designed from the published sequence of the human genes11 12 : AR (sense), 5'-AGATGGGCTTGACTTTCCCAGAAAG-3'; AR (antisense), 5'-ATGGCTGTCATTCAGTACTCCTGGA-3'.
Competition-based quantitative RT-PCR was performed with an AR competitor template as described elsewhere.12
Statistical Analysis
AR mRNA values are expressed as mean±SEM. Statistical
significance was analyzed with Fishers exact test.
Lipid-loading results are also expressed as mean±SEM of at least
triplicate wells per experiment per condition for each male and female
donor. Results for each condition in each donor were calculated as a
percentage of the control values (100%). Statistical significance by
an independent-samples t test, Fischers exact test where
n
6, or a 1-way ANOVA for trend, as appropriate, was inferred at a
2-sided value of P<0.05.
| Results |
|---|
|
|
|---|
|
Effects of Androgen Exposure on Macrophage Lipid
Loading
The functional effects of this sex difference in AR expression
were then explored. Androgen exposure was associated with a
dose-dependent increase in intracellular CE content in male-donor MDMs
(n=9) (CE as a percentage of control, 109±10%, 117±3%, and 120±4%
for DHT 4, 40, and 400 nmol/L, respectively; P=0.002 by
ANOVA; Figure 2
). This
androgen-associated increase in CE accumulation was abrogated by
coincubation with the nonsteroidal AR antagonist HF (CE
content 95±8% for DHT 40 nmol/L and HF 400 nmol/L versus controls,
P=0.58). HF 400 nmol/L alone did not alter CE content
significantly (110±7%, P=0.1). Free
cholesterol (FC) content in male-donor macrophages
was not altered significantly by androgen exposure (P=0.40).
Absolute lipid-loading values in macrophages from 1 male donor
(but comparable in nature to the others) were as follows: for control
cells, CE 62±4 nmol/mg cell protein, FC 139±16 nmol/mg; and for DHT
40 nmol/Ltreated cells, CE 78±2 nmol/mg cell protein, FC 132±11
nmol/mg cell protein.
|
In contrast to the male-donor cells, CE content in female-donor macrophages (n=4) did not increase with androgen exposure (CE 86±11% and 75±15% for DHT 40 nmol/L and 400 nmol/L, respectively, P>0.2 versus controls). Similarly, FC accumulation was unchanged by androgen treatment.
| Discussion |
|---|
|
|
|---|
Sex differences have previously been documented in the levels of AR message found in macrophage-like synoviocytes,13 and in rat aortic smooth muscle cells,14 androgen-receptor protein levels are higher in male than in female animals. In these experimental studies, however, no functional correlates of these observations were investigated. In this first study of AR expression in human MDMs, the observed sex difference in AR message was associated with enhanced lipid loading by male- but not female-donor cells, consistent with a proatherogenic effect.
Dihydrotestosterone was used in these experiments because it is a potent, nonaromatizable physiological androgen that is specific for the AR. This avoids the potentially confounding effects of estrogenic metabolites that arise from the aromatization of testosterone,15 noting that estrogens may also influence macrophage lipid loading.9 An acetylated form of LDL was used in these experiments, because acetylated LDL is the standard type of modified LDL used in lipoprotein uptake experiments and a specific ligand for the scavenger receptor, which may play a critical role in foam cell formation (although additional pathways of modified LDL uptake also occur in vivo).16
In summary, the androgen dihydrotestosterone increases CE accumulation in MDMs from male but not female subjects. Because this effect is receptor-mediated, the most likely reason for its sex specificity relates to the significantly higher levels of AR mRNA found in male- than in female-donor macrophages. These data are consistent with a significant effect of androgen exposure on foam cell formation in men.
| Acknowledgments |
|---|
Received September 23, 1999; revision received November 4, 1999; accepted November 5, 1999.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. Ray, C. M. Herring, T. A. Markel, P. R. Crisostomo, M. Wang, B. Weil, T. Lahm, and D. R. Meldrum Deleterious effects of endogenous and exogenous testosterone on mesenchymal stem cell VEGF production Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2008; 294(5): R1498 - R1503. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. C. Ng, S. Nakhla, A. Baoutina, W. Jessup, D. J. Handelsman, and D. S. Celermajer Dehydroepiandrosterone, an adrenalandrogen, increases human foam cell formation: a potentially pro-atherogenic effect J. Am. Coll. Cardiol., December 3, 2003; 42(11): 1967 - 1974. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. C. Ng, C. M. Quinn, J. A. McCrohon, S. Nakhla, W. Jessup, D. J. Handelsman, D. S. Celermajer, and A. K. Death Androgens Up-Regulate Atherosclerosis-Related Genes in Macrophages From Males But Not Females: Molecular Insights Into Gender Differences in Atherosclerosis J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1306 - 1313. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Griffiths, M. A. Sader, M. R. Skilton, J. A. Harmer, and D. S. Celermajer Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease J. Am. Coll. Cardiol., August 20, 2003; 42(4): 698 - 704. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Schneider, M. G. Schwacha, T. S. A. Samy, K. I. Bland, and I. H. Chaudry Androgen-mediated modulation of macrophage function after trauma-hemorrhage: central role of 5{alpha}-dihydrotestosterone J Appl Physiol, July 1, 2003; 95(1): 104 - 112. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Y. Liu, A. K. Death, and D. J. Handelsman Androgens and Cardiovascular Disease Endocr. Rev., June 1, 2003; 24(3): 313 - 340. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. C. W. Wu and A. von Eckardstein Androgens and Coronary Artery Disease Endocr. Rev., April 1, 2003; 24(2): 183 - 217. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Sullivan, J. E. Evans, J. M. Cermak, K. L. Krenzer, M. R. Dana, and D. A. Sullivan Complete Androgen Insensitivity Syndrome: Effect on Human Meibomian Gland Secretions Arch Ophthalmol, December 1, 2002; 120(12): 1689 - 1699. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Lukyanenko, J.-J. Chen, and J. C. Hutson Testosterone Regulates 25-Hydroxycholesterol Production in Testicular Macrophages Biol Reprod, November 1, 2002; 67(5): 1435 - 1438. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Kenny, K. M. Prestwood, C. A. Gruman, G. Fabregas, B. Biskup, and G. Mansoor Effects of Transdermal Testosterone on Lipids and Vascular Reactivity in Older Men With Low Bioavailable Testosterone Levels J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2002; 57(7): M460 - 465. [Abstract] [Full Text] |
||||
![]() |
M. K.C. Ng, P. Y. Liu, A. J. Williams, S. Nakhla, L. P. Ly, D. J. Handelsman, and D. S. Celermajer Prospective Study of Effect of Androgens on Serum Inflammatory Markers in Men Arterioscler. Thromb. Vasc. Biol., July 1, 2002; 22(7): 1136 - 1141. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E Rossouw Hormones, genetic factors, and gender differences in cardiovascular disease Cardiovasc Res, February 15, 2002; 53(3): 550 - 557. [Full Text] [PDF] |
||||
![]() |
M. A. Sader and D. S. Celermajer Endothelial function, vascular reactivity and gender differences in the cardiovascular system Cardiovasc Res, February 15, 2002; 53(3): 597 - 604. [Full Text] [PDF] |
||||
![]() |
H. Igarashi, T. Kouro, T. Yokota, P. C. Comp, and P. W. Kincade Age and stage dependency of estrogen receptor expression by lymphocyte precursors PNAS, December 18, 2001; 98(26): 15131 - 15136. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hanke, C. Lenz, B. Hess, K.-D. Spindler, and W. Weidemann Effect of Testosterone on Plaque Development and Androgen Receptor Expression in the Arterial Vessel Wall Circulation, March 13, 2001; 103(10): 1382 - 1385. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |